China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its freeze-dried Haemophilus influenzae type B (Hib) conjugate vaccine.
Haemophilus influenzae, a Gram-negative bacterium, is a leading cause of acute lower respiratory tract infections in children. The bacterium can be categorized into capsular and non-capsular types. Non-capsular strains are known to cause conditions such as otitis media and sinusitis, while capsular strains typically result in infections that are secondary to blood flow invasion. These capsular strains are further classified into six serotypes based on the chemical composition of their capsular polysaccharides, with serotype B accounting for approximately 95% of invasive Haemophilus influenzae diseases.
The Hib vaccine developed by CanSino consists of purified Hib capsular polysaccharides covalently bound to tetanus toxoid proteins. Utilizing a freeze-dried formulation, the vaccine is designed to stimulate humoral immunity against Hib following vaccination, thereby providing a protective effect for those vaccinated.- Flcube.com
